Oncovir, Inc is a pharmaceutical corporation organized around development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Oncovir promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.
